− Patients Receiving Investigational ALN-AGT Experienced Dose-Dependent Reductions in Blood Pressure, Confirming Potential for RNAi-Mediated Angiotensinogen (AGT) Silencing as a Novel Therapeutic Approach for Hypertension – − Durable AGT Knockdown Through 12 Weeks Supports a Once Quarterly or Potentially Less Frequent Dosing Regimen – − ALN-AGT Generally Well Tolerated, with […]